Kornimate/medical-research-clean huggingface dataset:
registry of endocrine tumors (thyroid, parathyroid, adrenal, endocrine pancreas, endocrine digestive tube)

Conditions: Endocrine Tumor

Summary: this registry aims to collect informations about patients with endocrine tumors (thyroid, parathyroid, adrenal, endocrine pancreas, endocrine digestive tube) who undergo endocrine surgical procedures. this registry is part of the eurocrine project.

the eurocrine project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-european database. recording and accessing data at the european level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. eurocrine will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.

Eligibility criteria:
inclusion criteria: * patients who undergo surgical procedures for endocrine tumors at the university nancy brabois hospital exclusion criteria: * unable to receive clear information * refusal to sign the consent form

Keywords: adrenal thyroid parathyroid endocrine pancreas endocrine digestive tube
study to explore the effect of secukinumab, compared to placebo, on fat tissue and skin in plaque psoriasis patients

Conditions: Plaque Psoriasis

Summary: this study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.

this was a randomized, double-blind, placebo-controlled, multicenter design. patients with moderate to severe plaque psoriasis received secukinumab 300 mg or placebo, with randomization stratified by body weight (\< 90 kg, ≥ 90 kg). there were 5 periods to the study: screening (1 to 4 weeks), double-blind treatment period (12 weeks), double-blind induction period (4 weeks), open-label treatment period (36 weeks), and follow-up period (1 week). during the double-blind treatment period, all patients attended study visits at baseline, weeks 1, 2, 3, 4, 8, and 12, and all doses of study treatment were self-administered at the study site. patients underwent lesional (ls) and non-lesional (nl) skin biopsies at baseline and week 12. assessments for the primary efficacy variable were performed at week 12 before patients received their week 12 dose. during the double-blind induction period, patients randomized to placebo were switched to secukinumab 300 mg for the remainder of the study. k16 and skin histology/biomarkers were assessed from skin biopsies. the psoriasis assessment and severity index (pasi) and the investigator's global assessment modified 2011 scale (iga mod 2011) were performed at specified study visits. safety was monitored by vital signs, weight, waist circumference, body mass index (bmi), and clinical laboratory tests (serum chemistry, hematology, highsensitivity c-reactive protein (hs-crp), hemoglobin a1c (hba1c), homeostatic assessment of insulin resistance (homa-ir), viral serology, serum and urine pregnancy).

Eligibility criteria:
inclusion criteria: * written informed consent must be obtained before any assessment is performed * clinical diagnosis of chronic plaque-type psoriasis at least 6 months prior to randomization * moderate to severe plaque psoriasis as defined at baseline by: * ≥10% body surface area (bsa) involvement and * pasi total score of ≥12 and * iga mod 2011 score of ≥3 (based on a scale of 0-4) exclusion criteria: * forms of diagnosed psoriasis other than chronic plaque psoriasis * medication-induced or medication exacerbated psoriasis * previous exposure to secukinumab or any other biologic drug directly targeting il-17a or il-17ra receptors * ongoing use of prohibited treatments * pregnant or nursing (lactating) women other protocol-defined inclusion/exclusion criteria may apply

Keywords: scalp psoriasis plaque psoriasis secukinumab ain457 biologic monoclonal antibod psoriasis ain457a
the effect of laughter yoga on vasomotor symptoms and sleep quality

Conditions: Vasomotor; Syndrome; Sleep

Summary: the research was planned as a prospective, randomized controlled experimental study to determine the effect of online laughter yoga applied to menopausal women on vasomotor symptoms (vms) and sleep quality. research hypotheses ar below; h0: online laughter yoga has no effect on vms. h1: online laughter yoga has an effect on vms. h0: online laughter yoga has no effect on sleep quality. h1: online laughter yoga has an effect on sleep quality.

the sample will consist of 82 menopausal women aged 40-60 years and experiencing at least one of the vms. intervention group: online laughter yoga will be applied to women by a researcher who has an internationally approved certificate. the intervention group will receive eight online laughter yoga sessions, two sessions per week for four weeks. in this study, the number of laughter yoga sessions was determined in line with the studies in the literature. each laughter yoga session is planned to last approximately 40-45 minutes. each session of laughter yoga consists of clapping and warm-up exercises, deep breathing exercises, childlike play and laughter. no intervention will be applied to the control group.

Eligibility criteria:
inclusion criteria: * - enrolled in the menopause school, * signing the informed consent form, * willing to participate in the research, * able to read and write turkish, * open to communication, * those who are between the ages of 40-60 and have not experienced menstruation for at least one year, * experiencing at least one of the vasomotor symptoms * a vms severity of at least 4 according to the visual analog scale, * not using drugs for the treatment of vasomotor symptoms, * no chronic disease * regular laughter yoga is not practiced, * those who have not entered the menopause surgically, * women without psychiatric problems exclusion criteria: * - not enrolled in menopause school, * not signing the informed consent form, * not willing to participate in the research, * cannot read and write turkish, * unable to communicate * less than 40 years old, over 60 years old, experienced menstruation for at least one year, * not experiencing vasomotor symptoms, * vms severity is less than 4 according to the visual analog scale, * using drugs for the treatment of vasomotor symptoms, * having a chronic disease, * regular laughter yoga practice * those who have surgically entered the menopause, * women with psychiatric problems

Keywords: vasomotor symptoms sleep quality menopause laughter yoga laughter therapy
evaluation of pancreatic tissue penetration of meronem® in the prophylaxis of septic complications in severe pancreatitis

Conditions: Pancreatitis

Summary: to measure meropenem pancreatic tissue penetration in subjects with severe pancreatitis requiring surgery between 30 to 60 minutes after a bolus of 1 g iv meropenem given during the induction period of anesthesia.


Eligibility criteria:
inclusion criteria: * subjects with diagnosis of severe pancreatitis requiring surgery according to the protocol of each institution. * informed consent signed by the subject * subjects who have received prophylactic antibiotics for previous invasive procedures different from surgery may be included exclusion criteria: * will of the subject not to be included * subjects who have not signed the informed consent * subjects with known hypersensibility to carbapenems, penicillins, or cephalosporins
radioguided selective neck dissection for staging and treatment of oral cavity and oropharyngeal squamous cell carcinoma

Conditions: Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma

Summary: the purpose of the study is to assess the role of lymphoscintigraphy as a simple and widely accessible method with a favorable cost/benefit ratio in improving oral cavity and oropharyngeal squamous cell carcinoma staging and surgical appropriateness and implementing a tailored surgical approach to cervical lymph node dissection.


Eligibility criteria:
inclusion criteria: * accepted informed consent * preoperative histological diagnosis of oral cavity or oropharyngeal squamous cell carcinoma * patients fit to surgery of the primitive tumor and neck dissection (according to the general health condition and the clinical tumor stage) exclusion criteria: * rejected informed consent * patients not fit to surgery (according to the general health condition and the clinical tumor stage) * pregnant women
effect of lidocaine phonophoresis versus pulsed ultrasound on myofascial pain syndrome in athletic children

Conditions: Treatment Side Effects

Summary: a topical anesthetic gel lidocaine has been widely used as a local anesthetic to reduce the pain and discomfort. it provides local analgesia by blocking the initiation and transmission of impulses. lidocaine topical anesthetic gel allows the use of high concentrations of the anesthetic bases without concern about local irritation, uneven absorption or systemic toxicity (argoff, 2000 ). so, the aim of this study is to compare between the effect of lidocaine phonophoresis and pulsed ultrasound in myofascial pain syndrome in swimmers children.

fourty five children (athletic swimmers) participated in this study, and were classified into three groups ; first control group a : this group consisted of fifteen children were receiving traditional physical therapy program. second study group b: this group consisted of fifteen children were receiving pulsed ultrasound in addition to traditional physical therapy program as the same as in group a. third study group c: this group consisted of fifteen children were receiving lidocaine phonophoresis in addition to traditional physical therapy program as the same as in group a. treatment program in the three groups applied three times a week for three successive months. the study was done in the outpatient clinic of ismailiy sporting club, ismailia, egypt.

Eligibility criteria:
inclusion criteria: * • age range from 10 to 14 years. * all children have regional neck pain complaint. * tenderness in cervical trigger points in the midpoint of the upper border of trapezius muscle, from grade ii to grade iv according to tenderness grading scheme (hubbard and berkoff, 1993) (appendix i ) ● the diagnosis of an active mtrp in the upper trapezius according to (ardiçet al . , 2002 and bruno, 2005) exclusion criteria: * • neurological disorders. * dermatological disorders. * acute trauma prior to the study. * fibromyalgia, systemic disease and drug allergy history were excluded from the study. * having myofascial trigger points injection. * chronic pain in both sides of the body.

Keywords: myofascial pain syndrome, pain quality
low frequency shock wave therapy for improving post-prostatectomy erectile dysfunction: a prospective pilot study

Conditions: Erectile Dysfunction

Summary: the primary objective of this study is to evaluate changes in erectile function (ef) before versus after 8 bi-weekly treatments of low-intensity extracorporeal shock wave therapy (lieswt) via iief-ef (the erectile function domain of the international index of erectile function) scores.

the secondary objectives of this study are to evaluate changes in the following elements before versus after 8 bi-weekly treatments of lieswt: a. ef categorical improvement. b. other validated measures of ef (sep2 (question 2 of the sexual encounter profile), sep3 (question 3 of the sexual encounter profile), gaq (global assessment question), ehs (erection hardness score)), and the remaining domains of the iief score (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction), as well as the total iief score. c. harms/safety: to evaluate treatment tolerance and potential adverse events.

Eligibility criteria:
inclusion criteria: * the patient has given his informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is a man at least 18 years old and less than 80 years old * the patient has been in a stable, sexual relationship with only one other person for at least the past three months * the patient is consulting for erectile dysfunction lasting for over 6 months * the patient had a prostatectomy 18 to 60 months ago * the patient has an erectile function domain score on the international index of erectile function questionnaire between 6 and 25 * the patient has at least a natural tumescence during sexual stimulation (erection hardness score ≥ 1) * the patient has not had phosphodiesterase type 5 inhibitor treatment for the month preceding inclusion * the patient is available for 8 months of follow-up and agrees to participate in all study visits exclusion criteria: * the patient is participating in another interventional study, or has participated in another interventional study within the past 3 months * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, or is an adult under guardianship * it is impossible to correctly inform the patient, or the patient refuses to sign the consent * complete anerection * untreated testosterone deficiency * neurological disease * psychiatric disease * anatomical malformation of the penis * chronic haematological pathology with significant clinical impact * oral or injectable antiandrogen treatment * the patient is taking blood thinners and has an international normalized ratio \> 3 * history of erectile dysfunction before the prostatectomy
reviewing daa efficacy managing patient treatment in online neighbourhoods

Conditions: Hepatitis C

Summary: redemption (reviewing daa efficacy managing patient treatment in online neighbourhoods) is observing and collating the treatment course, safety profile, and outcomes of patients around the world who are choosing to self import generic versions of the direct acting antivirals sofosbuvir, ledipasvir and daclatasvir from countries like china, india and bangladesh.

the high prices of hepatitis c virus (hcv) direct acting antiviral (daa) medications in many countries have led patients to seek out less expensive generic alternatives. the efficacy and safety of these generic medications has not been formally demonstrated in clinical practice. the primary goal of redemption is to collate the clinical results of these generic medications. the secondary goal is to answer efficacy questions for which there is currently insufficient trial data available - for example sofosbuvir+daclatasvir appears to be an inexpensive pan genotypic solution to treat hcv globally but this is supported by a total n of less than 1000, and in some common genotypes, such as hcv genotype 2, by an n of only 52 making for a wide margin of error and a high degree of uncertainty.

Eligibility criteria:
inclusion criteria: quantitative hcv rna \> 100 exclusion criteria: contraindications to daa medications
robot-assisted gait training in multiple sclerosis subjects

Conditions: Multiple Sclerosis

Summary: aims of the study: this is a randomized-controlled trial to test the effects of robot-assisted gait training on locomotor function and motor unit firing rate in multiple sclerosis subjects with severe gait impairments. the control group will be treat with conventional physical therapy. subjects and methods: 60 multiple sclerosis patients will be recruited in two outpatient rehabilitation clinics. informed consent will be obtained. participants will be randomized to robot-assisted gait training (experimental group) or conventional therapy (control group) through a randomization stratification approach, according to a block randomization of 4. the experimental group will receive 12 robot-assisted gait training sessions over 6 weeks (2 sessions/week). the control group will receive 12 conventional therapy sessions over 6 weeks (2 sessions/week), that will focus on gait training. primary outcome measures will be both neurophysiological measures (motor unit firing rate characteristics) and clinical test for gait speed (10m walking test). secondary outcome measures will include: clinical tests of walking endurance (six minute walking test), balance (berg balance test) and mobility (up and go test). clinical assessment of lower-extremities spasticity (modified ashworth scale), motor fatigue (fatigue severity scale), depression (phq-9) and quality of life (sf-36) will be monitored. subject acceptance and confidence in the treatments will be track with a visual analog scale. outcome measures will be assessed the week prior to treatment initiation (t0), after 6 sessions (t1), the week after the end of treatment (t2) and at 3 months follow-up (t3) to evaluate treatments retention, by a clinician blinded to the treatment.


Eligibility criteria:
inclusion criteria: * males and females, community dwelling, age 18 or older * diagnosis of multiple sclerosis in a stable phase, with relapses \> 6 months prior to study enrollment * moderate to severe gait impairments referred to expanded disability status scale (edss) between 6 and 7 exclusion criteria: * neurologic conditions in addition to multiple sclerosis that may affect motor function * medical conditions likely to interfere with the ability to safely complete the study * impaired cognitive functioning: mini mental status examination \< 24 * severe lower-extremities spasticity or contractures that may limit range of motion(ashworth score \>4 for hip, knee or ankle flexors/extensors

Keywords: multiple sclerosis gait rehabilitation
a clinical trial of intravenous (iv) ganaxolone in women with postpartum depression

Conditions: Depression; Depressive Disorder; Depression, Postpartum; Behavioral Symptoms; Mood Disorders; Mental Disorders; Puerperal Disorders; Pregnancy Complications; Postpartum; PPD

Summary: this study will evaluate the safety, pharmacokinetics and efficacy of iv administration of ganaxolone in women with postpartum depression

this study will explore whether ganaxolone is safe and well tolerated in women suffering from ppd. in addition, ganaxolone's efficacy in treating depressive symptoms will be assessed through a set of exploratory analyses. plasma levels of ganaxolone will be determined through pharmacokinetic analysis. the study results will be used to select a ganaxolone dose and dosing regimen for further development in ppd.

Eligibility criteria:
inclusion criteria: * participant experienced a major depressive episode, which started between the start of the third trimester and 4 weeks following delivery. the major depressive episode must be diagnosed according to mini international neuropsychiatric interview (mini) 7.0 interview * participant gave birth in the last 6 months * participant has a hamilton depression rating scale 17-item version (hamd17) score of ≥ 26 at screening * participant must agree to stop breastfeeding from start of study treatment or must agree to temporarily cease giving breast milk to her infant(s) exclusion criteria: * current or past history of any psychotic illness, including major depressive episode with psychotic features * history of suicide attempt within the past 3 years * active suicidal ideation * history of bipolar i disorder * history of seizure disorder

Keywords: postpartum care postpartum depression
study on post-acute myocardial infarction ventricular defect: outcome evalutation in relation to surgical timing

Conditions: Myocardial Infarction (MI); Heart Disease

Summary: the main objective of the study is to identify the optimal surgical timing for the treatment of intraventricular defects after acute myocardial infarction.

identify the optimal timing for the treatment of post-infarction ventricular defect, considering the time interval between the clinical-instrumental diagnosis and the surgical intervention.

Eligibility criteria:
inclusion criteria: * patients over eighteen years of age * patients with post-myocardial infarction ventricular septal defect treated surgically * patients who have signed the informed consent exclusion criteria: * patients with post-infarction ventricular septal defect treated with medical/conservative therapy * patients with ventricular septal defects not due to acute myocardial infarction
effect of serum vitamin d level on the efficacy of peg-interferon treatment in chb

Conditions: Chronic Hepatitis b

Summary: in recent years, vitamin d (vd) has received much attention in the fields of host immune regulation, inflammation, fibrosis, cell proliferation and differentiation and tumor. vd works by binding to the vitamin d receptor (vdr). vdr is mainly distributed in giant cells, dendritic cells, t cells and lymphocytes. four snps of vdrs have been most studied: taqi (rs731236), foki (rs10735810), apai (rs7975232), and bsmi (rs1544410). at present, more and more patients have been treated with oral nucleotide/nucleoside analogues (nas) with direct antiviral drugs in china, and a large part of them show low expression of hbsag. clinical cure can be pursued for these patients, that is, hbsag turns negative. a number of studies have been carried out at home and abroad. in this study, we will recruit chb patients with low hbsag levels. they all will receive pegylated interferon treatment and were randomly assigned to a vitamin d treatment or a control group. a final assessment will be made to determine whether vitamin d levels would affect the clearance rate of hbsag.


Eligibility criteria:
inclusion criteria: 1.according with the diagnosis of chronic hepatitis b in the guideline of china in 2015 2.18-60 years old 3.more than 1 year history of nucleot(s)ide analogues therapy with hbsag ≤1500 iu/ml, negative hbeag and hbv dna\<100 iu/ml 4.no contraindications of interferon exclusion criteria: 1. allergy to interferon 2. alanine transaminase \>10 times of upper limit of normal(uln) or total bilirubin \>2 times of uln 3. existing or previous decompensated liver cirrhosis 4. white blood cells or platelet below the lower limit of normal 5. existing severe organ injury 6. combined with autoimmune diseases, psychiatric diseases, diabetes or thyroidism 7. confirmed or suspected malignant tumors 8. before or after transplantation 9. using immunosuppressor 10. pregnant or having a planned parenthood in 2 years 11. alcohol or drug addicted 12. infected by hiv 13. any conditions that is unsuitable to interferon therapy according to the doctors' judgement

Keywords: hepatitis b vitamin d interferon